Since it is well known that IL-1β is a potent activator of RA-FLS (32, 33), as an internal control in these experiments we neutralized the IL-1β present in the inflamed synovial fluid by using canakinumab. This evidence concerns the gene IL1B and rheumatoid arthritis.